The response to treatment with glaunisertib and TGF-β1 was investigated through analyzing the transcriptome of metastatic HCC cell lines using next-generation sequencing-based massive analysis of cDNA ends. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.